Marketing Authorization Application for voclosporin for treatment of lupus nephritis filed with European Medicines Agency

Lupus nephritis (LN) is complication of SLE that seriously impacts kidneys. In January 2021, the FDA approved voclosporin, a novel calcineurin inhibitor, in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active LN.

Source:

Biospace Inc.